glp 1 receptor agonists canada CPHA: Now Second-Largest GLP-1 User Market Globally Central glucagon-like peptide 1 receptor
Description
Legend: * Injection site nodule
doi:10.1111/j.1365-2982.2007.01079.x Schirra J, Nicolaus M, Woerle HJ, Struckmeier C, Katschinski M, Gke B
Marassi M, Cignarella A, Russo GT, Nollino L, Strazzabosco M, Marzullo P, et al
The drug company said most of its revenue boosts are due to skyrocketing sales of two of its most popular GLP-1 medications (i.e., Mounjaro and Zepbound)
It is also in the midst of early trials for LX9851, a non-incretin obesity drug that would be a potential alternative to GLP-1s
